Skip to main content
ConductScienceScienceDex
NIH funding notice RFA-DA-25-053

Harnessing Artificial Intelligence and Polypharmacology to Discover Pharmacotherapeutics for Substance Use Disorders (R41/R42 Clinical Trials Not Allowed)

Closed on July 25, 2024.

Posted
January 29, 2024
Close date
July 25, 2024
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

2 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $797,243 in first-year total cost, median $398,622.

Most frequent study sections

  1. Special Emphasis Panel[ZDA1 DRO-S (J1)]2

Most frequent institutions

  1. CALLENTIS CONSULTING GROUP LLC1
  2. DARK MATTER THERAPEUTICS, INC.1
Competing awards under RFA-DA-25-053 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2025AI-Powered chemical-pathway-patient-directed polypharmacology for OUD therapy1R41DA062978-01XIE, LEIDARK MATTER THERAPEUTICS, INC., DE$399,414ZDA1
2025AI Platform to Discover Therapeutics for Substance Use Disorders1R41DA062993-01LAUVER, DALE ADAMCALLENTIS CONSULTING GROUP LLC, TX$397,829ZDA1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-10-0.1.1. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.

Start your CVHow the NIH biosketch works
RFA-DA-25-053: Harnessing Artificial Intelligence and Polypharmacology to Discover Pharmacotherapeutics for Substance Use Disorders (R41/R42 Clinical Trials Not Allowed) | ScienceDex | ConductScience